Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S.

Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and ...

“The present studies were performed to extend our knowledge of GZ17-6.02 biology from that known in solid tumor cell types such as prostate cancer cells to liquid tumor cell types, for example, ...

Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and ...

The MarketWatch News Department was not involved in the creation of this content. First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) ...

TOKYO--(BUSINESS WIRE)-- On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored ...

Mycosis fungoides was the first type of lymphoma to be treated with radiation (Scholz, 1902). Since its use in the early 1900s, technical advances have led to the development of electron beam ...

First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company’s ...

Support groups and foundations can be invaluable for patients with mycosis fungoides and their families and caregivers. One of the most well-recognized organizations specifically for patients with ...